FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2924683704> ?p ?o ?g. }

• W2924683704 endingPage "1496" @default.
• W2924683704 startingPage "1485" @default.
• W2924683704 abstract "Biologics have improved the treatment of rheumatic diseases, resulting in better outcomes. However, their high cost limits access for many patients in both North America and Latin America. Following patent expiration for biologicals, the availability of biosimilars, which typically are less expensive due to lower development costs, provides additional treatment options for patients with rheumatic diseases. The availability of biosimilars in North American and Latin American countries is evolving, with differing regulations and clinical indications. The objective of the study was to present the consensus statement on biosimilars in rheumatology developed by Pan American League of Associations for Rheumatology (PANLAR). Using a modified Delphi process approach, the following topics were addressed: regulation, efficacy and safety, extrapolation of indications, interchangeability, automatic substitution, pharmacovigilance, risk management, naming, traceability, registries, economic aspects, and biomimics. Consensus was achieved when there was agreement among 80% or more of the panel members. Three Delphi rounds were conducted to reach consensus. Questionnaires were sent electronically to panel members and comments about each question were solicited. Eight recommendations were formulated regarding regulation, pharmacovigilance, risk management, naming, traceability, registries, economic aspects, and biomimics. The recommendations highlighted that, after receiving regulatory approval, pharmacovigilance is a fundamental strategy to ensure safety of all medications. Registries should be employed to monitor use of biosimilars and to identify potential adverse effects. The price of biosimilars should be significantly lower than that of reference products to enhance patient access. Biomimics are not biosimilars and, if they are to be marketed, they must first be evaluated and approved according to established regulatory pathways for novel biopharmaceuticals. • Biologics have improved the treatment of rheumatic diseases. • Their high cost limits access for many patients in both North America and Latin America. • Biosimilars typically are less expensive, providing additional treatment options for patients with rheumatic diseases. • PANLAR presents its consensus on biosimilars in rheumatology" @default.
• W2924683704 created "2019-04-01" @default.
• W2924683704 creator A5000779664 @default.
• W2924683704 creator A5002895469 @default.
• W2924683704 creator A5005654169 @default.
• W2924683704 creator A5007165867 @default.
• W2924683704 creator A5010615821 @default.
• W2924683704 creator A5017740190 @default.
• W2924683704 creator A5022145559 @default.
• W2924683704 creator A5028063859 @default.
• W2924683704 creator A5030234332 @default.
• W2924683704 creator A5031227134 @default.
• W2924683704 creator A5031991848 @default.
• W2924683704 creator A5033432665 @default.
• W2924683704 creator A5044148042 @default.
• W2924683704 creator A5045294576 @default.
• W2924683704 creator A5052584081 @default.
• W2924683704 creator A5053392621 @default.
• W2924683704 creator A5054398877 @default.
• W2924683704 creator A5057538503 @default.
• W2924683704 creator A5060754450 @default.
• W2924683704 creator A5061889655 @default.
• W2924683704 creator A5062238412 @default.
• W2924683704 creator A5062781235 @default.
• W2924683704 creator A5070214050 @default.
• W2924683704 creator A5076855596 @default.
• W2924683704 creator A5078570634 @default.
• W2924683704 creator A5079933997 @default.
• W2924683704 creator A5080668536 @default.
• W2924683704 creator A5082221558 @default.
• W2924683704 creator A5085738116 @default.
• W2924683704 creator A5087789631 @default.
• W2924683704 creator A5090154943 @default.
• W2924683704 date "2019-03-27" @default.
• W2924683704 modified "2023-10-17" @default.
• W2924683704 title "PANLAR consensus statement on biosimilars" @default.
• W2924683704 cites W1966243551 @default.
• W2924683704 cites W1969178277 @default.
• W2924683704 cites W1980563301 @default.
• W2924683704 cites W1981336058 @default.
• W2924683704 cites W1985598489 @default.
• W2924683704 cites W2000488177 @default.
• W2924683704 cites W2010535261 @default.
• W2924683704 cites W2016256662 @default.
• W2924683704 cites W2026641908 @default.
• W2924683704 cites W2027654506 @default.
• W2924683704 cites W2028530521 @default.
• W2924683704 cites W2052372237 @default.
• W2924683704 cites W2095265954 @default.
• W2924683704 cites W2108344016 @default.
• W2924683704 cites W2125430230 @default.
• W2924683704 cites W2131754054 @default.
• W2924683704 cites W2153919578 @default.
• W2924683704 cites W2160757315 @default.
• W2924683704 cites W2262703742 @default.
• W2924683704 cites W2288634714 @default.
• W2924683704 cites W2289244316 @default.
• W2924683704 cites W2293590090 @default.
• W2924683704 cites W2321862446 @default.
• W2924683704 cites W2340839875 @default.
• W2924683704 cites W2342581896 @default.
• W2924683704 cites W2462509855 @default.
• W2924683704 cites W2497463270 @default.
• W2924683704 cites W2530584466 @default.
• W2924683704 cites W4233021914 @default.
• W2924683704 cites W4241376415 @default.
• W2924683704 cites W4363603928 @default.
• W2924683704 cites W58316457 @default.
• W2924683704 doi "https://doi.org/10.1007/s10067-019-04496-3" @default.
• W2924683704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30915652" @default.
• W2924683704 hasPublicationYear "2019" @default.
• W2924683704 type Work @default.
• W2924683704 sameAs 2924683704 @default.
• W2924683704 citedByCount "8" @default.
• W2924683704 countsByYear W29246837042019 @default.
• W2924683704 countsByYear W29246837042020 @default.
• W2924683704 countsByYear W29246837042021 @default.
• W2924683704 countsByYear W29246837042023 @default.
• W2924683704 crossrefType "journal-article" @default.
• W2924683704 hasAuthorship W2924683704A5000779664 @default.
• W2924683704 hasAuthorship W2924683704A5002895469 @default.
• W2924683704 hasAuthorship W2924683704A5005654169 @default.
• W2924683704 hasAuthorship W2924683704A5007165867 @default.
• W2924683704 hasAuthorship W2924683704A5010615821 @default.
• W2924683704 hasAuthorship W2924683704A5017740190 @default.
• W2924683704 hasAuthorship W2924683704A5022145559 @default.
• W2924683704 hasAuthorship W2924683704A5028063859 @default.
• W2924683704 hasAuthorship W2924683704A5030234332 @default.
• W2924683704 hasAuthorship W2924683704A5031227134 @default.
• W2924683704 hasAuthorship W2924683704A5031991848 @default.
• W2924683704 hasAuthorship W2924683704A5033432665 @default.
• W2924683704 hasAuthorship W2924683704A5044148042 @default.
• W2924683704 hasAuthorship W2924683704A5045294576 @default.
• W2924683704 hasAuthorship W2924683704A5052584081 @default.
• W2924683704 hasAuthorship W2924683704A5053392621 @default.
• W2924683704 hasAuthorship W2924683704A5054398877 @default.
• W2924683704 hasAuthorship W2924683704A5057538503 @default.
• W2924683704 hasAuthorship W2924683704A5060754450 @default.

• next